Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, pharmacokinetics (PK) and efficacy of Myozyme treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
5
20 mg/kg qow
Sophia Kinderziekenhuis, Erasmus MC
Rotterdam, Netherlands
safety and PK profile rhGAA
Time frame: 74 weeks
FVC
Time frame: 74 weeks
MMT
Time frame: 74 weeks
Effect of treatment on muscle function
Time frame: 74 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.